Rie Sugimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rie Sugimoto has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
Takeshi Senju
Department of Gastroenterology Kyushu Rosai Hospital Kitakyushu Japan
7 shared publicationsAritsune Ooho
6 shared publications- Masatake Tanaka
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
6 shared publications Takeaki Satoh
6 shared publicationsToshimasa Koyanagi
6 shared publications- Eiichi Ogawa
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan
5 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in Annals of Hepatology
Impact of metabolic dysfunction-associated steatotic liver disease on the development of hepatocellular carcinoma after HCV cure
- 9 October 2026
- Published by Elsevier in Annals of Hepatology
Open AccessImpact of metabolic dysfunction-associated steatotic liver disease on the development of hepatocellular carcinoma after HCV cure
- Open Access
Hypercoagulability Predicts Survival and Reflects NET-Associated Thromboinflammation in Advanced Pancreatic Cancer
Background: Cancer-associated thrombosis is a major complication in pancreatic cancer; however, its true burden and prognostic significance remain unclear, largely owing to under-detection of asymptomatic events. In addition, the clinical relevance of cancer-related hypercoagulability and neutrophil extracellular traps (NETs), which may link thrombosis and tumor biology, has not been adequately evaluated in advanced pancreatic cancer. Methods: In this prospective study, newly diagnosed patients with unresectable pancreatic ductal adenocarcinoma underwent systematic screening for venous thromboembolism (VTE) at baseline, followed by longitudinal surveillance. Circulating coagulation markers and NET-related biomarkers were analyzed. Associations among VTE, hypercoagulability, NET-related biomarkers, and overall survival (OS) were evaluated. Results: Among 134 patients, VTE was detected at diagnosis in 28.4%, with the majority being asymptomatic. Hypercoagulability and NET-related biomarkers were significantly associated with VTE occurrence. Patients with baseline VTE (6.2 vs. 12.1 months, p = 0.002) and hypercoagulability (7.7 vs. 15.2 months, p = 0.002) demonstrated shorter OS. In multivariate analysis, hypercoagulability, but not baseline VTE, remained independently associated with inferior OS (hazard ratio 2.03, 95% confidence interval 1.27–3.27). Notably, the adverse prognostic impact of hypercoagulability was consistently observed across nearly all predefined clinical subgroups. Furthermore, a reduction in or normalization of D-dimer levels following anticoagulant therapy was associated with prolonged survival. Conclusions: Hypercoagulability, rather than overt thrombotic events, independently predicts survival outcomes in advanced pancreatic cancer. These findings support a biology-driven approach to thrombosis assessment and indicate that monitoring and therapeutic modulation of hypercoagulability may improve risk stratification and clinical management in this population.
Open AccessHypercoagulability Predicts Survival and Reflects NET-Associated Thromboinflammation in Advanced Pancreatic Cancer
Background: Cancer-associated thrombosis is a major complication in pancreatic cancer; however, its true burden and prognostic significance remain unclear, largely owing to under-detection of asymptomatic events. In addition, the clinical relevance of cancer-related hypercoagulability and neutrophil extracellular traps (NETs), which may link thrombosis and tumor biology, has not been adequately evaluated in advanced pancreatic cancer. Methods: In this prospective study, newly diagnosed patients with unresectable pancreatic ductal adenocarcinoma underwent systematic screening for venous thromboembolism (VTE) at baseline, followed by longitudinal surveillance. Circulating coagulation markers and NET-related biomarkers were analyzed. Associations among VTE, hypercoagulability, NET-related biomarkers, and overall survival (OS) were evaluated. Results: Among 134 patients, VTE was detected at diagnosis in 28.4%, with the majority being asymptomatic. Hypercoagulability and NET-related biomarkers were significantly associated with VTE occurrence. Patients with baseline VTE (6.2 vs. 12.1 months, p = 0.002) and hypercoagulability (7.7 vs. 15.2 months, p = 0.002) demonstrated shorter OS. In multivariate analysis, hypercoagulability, but not baseline VTE, remained independently associated with inferior OS (hazard ratio 2.03, 95% confidence interval 1.27–3.27). Notably, the adverse prognostic impact of hypercoagulability was consistently observed across nearly all predefined clinical subgroups. Furthermore, a reduction in or normalization of D-dimer levels following anticoagulant therapy was associated with prolonged survival. Conclusions: Hypercoagulability, rather than overt thrombotic events, independently predicts survival outcomes in advanced pancreatic cancer. These findings support a biology-driven approach to thrombosis assessment and indicate that monitoring and therapeutic modulation of hypercoagulability may improve risk stratification and clinical management in this population.
- Open Access
- 12 March 2026
- Published by S. Karger AG in Liver Cancer
- p. 1-12
A Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial
Introduction: Atezolizumab plus bevacizumab combination therapy (atezo + bev) has been successfully developed as a standard of care for patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh A; however, there is no established treatment for those with Child-Pugh B. This study aimed to evaluate the safety and efficacy of atezo + bev in patients with advanced HCC and Child-Pugh B. Methods: This multicenter, open-label, single-arm, phase II study enrolled patients with advanced HCC and a Child-Pugh score of 7 or 8 who had not received prior systemic therapy. Patients were administered atezolizumab (1,200 mg) plus bevacizumab (15 mg/kg) every 3 weeks. The primary endpoint was the frequency of serious adverse events (SAEs), assuming a threshold SAE of 68.5%. A binomial test with a one-sided significance level of 2.5% was employed for the primary analysis. Results: Among the 31 patients enrolled between December 2021 and April 2023, we set 30 eligible patients as the population for the safety and efficacy analyses. The frequency of SAEs was 23.3% (95% confidence interval [CI]: 9.9–42.3, p < 0.0001). Objective response rates according to RECIST v1.1 and the modified RECIST were 40.0% and 46.7%, respectively. The median progression-free and overall survival were 240 days (95% CI: 176–526 days) and 470 days (95% CI: 256–576 days), respectively. The mean ± SD Child-Pugh scores were 7.2 ± 0.4 at the start of treatment, maintained 7.0 ± 1.0 and 7.0 ± 1.2 at the third and sixth cycles, respectively, and was 7.6 ± 1.7 at the end of treatment. Conclusion: The atezo + bev regimen can be safely administered with demonstrable antitumor effects in patients with unresectable HCC and a Child-Pugh score of 7 or 8. Additional studies are warranted to confirm the usefulness of atezo + bev in this patient group.
- 12 March 2026
- Published by S. Karger AG in Liver Cancer
- p. 1-12
Open AccessA Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial
Introduction: Atezolizumab plus bevacizumab combination therapy (atezo + bev) has been successfully developed as a standard of care for patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh A; however, there is no established treatment for those with Child-Pugh B. This study aimed to evaluate the safety and efficacy of atezo + bev in patients with advanced HCC and Child-Pugh B. Methods: This multicenter, open-label, single-arm, phase II study enrolled patients with advanced HCC and a Child-Pugh score of 7 or 8 who had not received prior systemic therapy. Patients were administered atezolizumab (1,200 mg) plus bevacizumab (15 mg/kg) every 3 weeks. The primary endpoint was the frequency of serious adverse events (SAEs), assuming a threshold SAE of 68.5%. A binomial test with a one-sided significance level of 2.5% was employed for the primary analysis. Results: Among the 31 patients enrolled between December 2021 and April 2023, we set 30 eligible patients as the population for the safety and efficacy analyses. The frequency of SAEs was 23.3% (95% confidence interval [CI]: 9.9–42.3, p < 0.0001). Objective response rates according to RECIST v1.1 and the modified RECIST were 40.0% and 46.7%, respectively. The median progression-free and overall survival were 240 days (95% CI: 176–526 days) and 470 days (95% CI: 256–576 days), respectively. The mean ± SD Child-Pugh scores were 7.2 ± 0.4 at the start of treatment, maintained 7.0 ± 1.0 and 7.0 ± 1.2 at the third and sixth cycles, respectively, and was 7.6 ± 1.7 at the end of treatment. Conclusion: The atezo + bev regimen can be safely administered with demonstrable antitumor effects in patients with unresectable HCC and a Child-Pugh score of 7 or 8. Additional studies are warranted to confirm the usefulness of atezo + bev in this patient group.
- Open Access
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (3) , e2501104
Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis
PURPOSE: Germline BRCA (g BRCA ) mutations confer increased sensitivity to platinum-based chemotherapy and have been associated with improved survival across several malignancies. This study investigated the effect of g BRCA mutation status on the antitumor activity of modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (FOLFIRINOX; mFFX) in patients with advanced pancreatic cancer (APC). METHODS: This multicenter retrospective study was performed in 178 patients with histologically confirmed APC who received mFFX, comprising 17 g BRCA -positive and 161 g BRCA -negative individuals. Efficacy outcomes, including progression-free survival (PFS), objective response rate (ORR), and normalization rate of carbohydrate antigen 19-9 (CA19-9), were compared between groups using univariate and multivariate analyses. RESULTS: Median PFS was significantly longer in g BRCA -positive than in g BRCA -negative patients (10.6 v 5.3 months, P = .005). Independent predictors of PFS included g BRCA mutation (hazard ratio [HR], 3.65), disease extent (HR, 2.34), and previous chemotherapy (HR, 1.66). g BRCA- positive patients demonstrated a significantly higher ORR (82% v 34%, odds ratio, 0.11, P < .001) and CA19-9 normalization rate (69% v 10%, P < 0.01). ORR was associated with g BRCA status (HR, 0.04), disease extent (HR, 0.11), and treatment history (HR, 0.27). Among 68 responders, sustained shrinkage of both primary and metastatic tumors and continued CA19-9 decline were observed during the first 6 months in g BRCA- positive patients, whereas responses in g BRCA -negative patients plateaued after 3 months. Subgroup analysis revealed that most patient subgroups demonstrated superior PFS and ORR in the g BRCA -positive cohort compared with those in the g BRCA -negative cohort. CONCLUSION: g BRCA mutation status was strongly associated with enhanced radiologic and biological responses to mFFX in APC. Routine screening for g BRCA mutations may provide essential guidance in therapeutic decision making and substantially improve clinical outcomes in this population.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (3) , e2501104
Open AccessImpact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis
PURPOSE: Germline BRCA (g BRCA ) mutations confer increased sensitivity to platinum-based chemotherapy and have been associated with improved survival across several malignancies. This study investigated the effect of g BRCA mutation status on the antitumor activity of modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (FOLFIRINOX; mFFX) in patients with advanced pancreatic cancer (APC). METHODS: This multicenter retrospective study was performed in 178 patients with histologically confirmed APC who received mFFX, comprising 17 g BRCA -positive and 161 g BRCA -negative individuals. Efficacy outcomes, including progression-free survival (PFS), objective response rate (ORR), and normalization rate of carbohydrate antigen 19-9 (CA19-9), were compared between groups using univariate and multivariate analyses. RESULTS: Median PFS was significantly longer in g BRCA -positive than in g BRCA -negative patients (10.6 v 5.3 months, P = .005). Independent predictors of PFS included g BRCA mutation (hazard ratio [HR], 3.65), disease extent (HR, 2.34), and previous chemotherapy (HR, 1.66). g BRCA- positive patients demonstrated a significantly higher ORR (82% v 34%, odds ratio, 0.11, P < .001) and CA19-9 normalization rate (69% v 10%, P < 0.01). ORR was associated with g BRCA status (HR, 0.04), disease extent (HR, 0.11), and treatment history (HR, 0.27). Among 68 responders, sustained shrinkage of both primary and metastatic tumors and continued CA19-9 decline were observed during the first 6 months in g BRCA- positive patients, whereas responses in g BRCA -negative patients plateaued after 3 months. Subgroup analysis revealed that most patient subgroups demonstrated superior PFS and ORR in the g BRCA -positive cohort compared with those in the g BRCA -negative cohort. CONCLUSION: g BRCA mutation status was strongly associated with enhanced radiologic and biological responses to mFFX in APC. Routine screening for g BRCA mutations may provide essential guidance in therapeutic decision making and substantially improve clinical outcomes in this population.
- Open Access
- 31 August 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (9) , 490
Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects
The focus of treatment of hepatocellular carcinoma (HCC) has shifted significantly from local therapy to systemic drug therapy. Recently, the efficacy of drug therapy for HCC has made rapid progress. We have transitioned from eras of sorafenib monotherapy and sequential therapy with multiple tyrosine kinase inhibitors that slightly improved patient prognoses, to an era where the introduction of immunotherapy combining atezolizumab and bevacizumab has achieved further improvements in patient prognosis. The availability of highly effective drugs has expanded the range of diseases treatable by drug therapy. Additionally, instead of initiating drug therapy at advanced stages, combining it with local therapies such as transarterial chemoembolization at an earlier stage with the aim of achieving a cure has become possible, improving treatment outcomes further. Currently, the number of regimens available for HCC, including combinations of multiple drugs and local therapies, has increased, leading to numerous clinical trials. Additionally, HCC cases that were previously unresectable are now resectable after drug therapy, necessitating the establishment of a resectability classification system. This review summarizes the current evidence for drug therapy for HCC and discusses future treatment strategies, treatment combinations, and prospects.
- 31 August 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (9) , 490
Open AccessAdvances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects
The focus of treatment of hepatocellular carcinoma (HCC) has shifted significantly from local therapy to systemic drug therapy. Recently, the efficacy of drug therapy for HCC has made rapid progress. We have transitioned from eras of sorafenib monotherapy and sequential therapy with multiple tyrosine kinase inhibitors that slightly improved patient prognoses, to an era where the introduction of immunotherapy combining atezolizumab and bevacizumab has achieved further improvements in patient prognosis. The availability of highly effective drugs has expanded the range of diseases treatable by drug therapy. Additionally, instead of initiating drug therapy at advanced stages, combining it with local therapies such as transarterial chemoembolization at an earlier stage with the aim of achieving a cure has become possible, improving treatment outcomes further. Currently, the number of regimens available for HCC, including combinations of multiple drugs and local therapies, has increased, leading to numerous clinical trials. Additionally, HCC cases that were previously unresectable are now resectable after drug therapy, necessitating the establishment of a resectability classification system. This review summarizes the current evidence for drug therapy for HCC and discusses future treatment strategies, treatment combinations, and prospects.
- Open Access
- 9 August 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (10) , 2560-2567
Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment
Background and Aim: Long‐term nucleos(t)ide analog (NUC) therapy is essential for chronic hepatitis B (CHB) management. However, data on long‐term outcomes, particularly for patients switching to tenofovir alafenamide (TAF) and patients with chronic kidney disease (CKD), remain limited. This study aimed to evaluate the 5‐year virological effectiveness and renal safety of sequential TAF therapy, with a focus on those with pre‐existing CKD.Methods: This real‐world, multicenter, retrospective study included 414 CHB patients aged ≥ 18 years who switched from a prior NUC to TAF and were followed for at least 5 years. Patients were stratified based on renal function (CKD or non‐CKD) at baseline. Study endpoints included 5‐year virological efficacy, biochemical and fibrosis responses, and renal function changes.Results: Among the patients, 100 (24.2%) had CKD at the time of switching to TAF. Over 5 years, HBV DNA suppression rate increased from 85.0% to 100%, HBV DNA suppression with target not detected rate rose from 74.0% to 91.0%, and alanine aminotransferase normalization rate (AASLD criteria) improved from 66.0% to 79.0%, similar to the results of patients with non‐CKD. Estimated glomerular filtration rate remained stable regardless of baseline renal status or prior NUC regimen, demonstrating long‐term renal safety. There were no cases of HBV DNA breakthrough, including among those previously on combination NUCs. For patients with cirrhosis, the FIB‐4 index significantly improved over time (p = 0.008).Conclusions: Sequential TAF therapy demonstrated robust virological efficacy, biochemical and fibrosis improvements, and excellent renal safety over 5 years, irrespective of baseline renal function.
- 9 August 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (10) , 2560-2567
Open AccessFive‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment
Background and Aim: Long‐term nucleos(t)ide analog (NUC) therapy is essential for chronic hepatitis B (CHB) management. However, data on long‐term outcomes, particularly for patients switching to tenofovir alafenamide (TAF) and patients with chronic kidney disease (CKD), remain limited. This study aimed to evaluate the 5‐year virological effectiveness and renal safety of sequential TAF therapy, with a focus on those with pre‐existing CKD.Methods: This real‐world, multicenter, retrospective study included 414 CHB patients aged ≥ 18 years who switched from a prior NUC to TAF and were followed for at least 5 years. Patients were stratified based on renal function (CKD or non‐CKD) at baseline. Study endpoints included 5‐year virological efficacy, biochemical and fibrosis responses, and renal function changes.Results: Among the patients, 100 (24.2%) had CKD at the time of switching to TAF. Over 5 years, HBV DNA suppression rate increased from 85.0% to 100%, HBV DNA suppression with target not detected rate rose from 74.0% to 91.0%, and alanine aminotransferase normalization rate (AASLD criteria) improved from 66.0% to 79.0%, similar to the results of patients with non‐CKD. Estimated glomerular filtration rate remained stable regardless of baseline renal status or prior NUC regimen, demonstrating long‐term renal safety. There were no cases of HBV DNA breakthrough, including among those previously on combination NUCs. For patients with cirrhosis, the FIB‐4 index significantly improved over time (p = 0.008).Conclusions: Sequential TAF therapy demonstrated robust virological efficacy, biochemical and fibrosis improvements, and excellent renal safety over 5 years, irrespective of baseline renal function.
- Open Access
- 4 June 2025
- Published by MDPI AG in Preprints.org
Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects
The treatment of hepatocellular carcinoma has shifted significantly from the era of local therapy to the era of drug therapy, partly because of changes in background factors. Drug therapy for hepatocellular carcinoma has made rapid progress in recent years. We have moved from an era where sorafenib monotherapy was used to prolong survival, to an era of sequential therapy with multiple tyrosine kinase inhibitors, and further improvements in patient prognosis have been achieved with the introduction of immunotherapy com-bining atezolizumab and bevacizumab. The availability of highly effective drugs has expanded the range of diseases treatable by drug therapy. Additionally, instead of ini-tiating drug therapy at advanced stages, combining it with local therapies such as transarterial chemoembolization at an earlier stage with the aim of achieving a cure has become possible, improving treatment outcomes further. Currently, the number of regimens requiring consideration, involving combinations of multiple drugs and local therapies, has increased, leading to various trials being conducted. Additionally, cases of hepatocellular carcinoma that were previously unresectable have become resectable after drug therapy, necessitating the establishment of a resectability classification system. This review summarises the current evidence for drug therapy of hepatocellular carcinoma and discusses future treatment strategies, treatment combinations, and prospects.
- 4 June 2025
- Published by MDPI AG in Preprints.org
Open AccessAdvances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects
The treatment of hepatocellular carcinoma has shifted significantly from the era of local therapy to the era of drug therapy, partly because of changes in background factors. Drug therapy for hepatocellular carcinoma has made rapid progress in recent years. We have moved from an era where sorafenib monotherapy was used to prolong survival, to an era of sequential therapy with multiple tyrosine kinase inhibitors, and further improvements in patient prognosis have been achieved with the introduction of immunotherapy com-bining atezolizumab and bevacizumab. The availability of highly effective drugs has expanded the range of diseases treatable by drug therapy. Additionally, instead of ini-tiating drug therapy at advanced stages, combining it with local therapies such as transarterial chemoembolization at an earlier stage with the aim of achieving a cure has become possible, improving treatment outcomes further. Currently, the number of regimens requiring consideration, involving combinations of multiple drugs and local therapies, has increased, leading to various trials being conducted. Additionally, cases of hepatocellular carcinoma that were previously unresectable have become resectable after drug therapy, necessitating the establishment of a resectability classification system. This review summarises the current evidence for drug therapy of hepatocellular carcinoma and discusses future treatment strategies, treatment combinations, and prospects.
- 31 May 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria
Background and Aim: This study aimed to compare the therapeutic effects and safety of lenvatinib (LEN) plus transcatheter arterial chemoembolization (LEN‐TACE) and atezolizumab plus bevacizumab (Atez/Bev) as the first‐line therapies in patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond the up‐to‐seven criteria.Methods: We enrolled 768 patients with HCC treated with first‐line systemic therapy, and 154 patients were enrolled and categorized into either the LEN‐TACE therapy (n = 42) or Atez/Bev (n = 112) groups. After propensity score matching (PSM), 72 patients (LEN‐TACE group, n = 36; Atez/Bev group, n = 36) were analyzed.Results: After PSM, the median progression‐free survival showed no significant differences between the LEN‐TACE and Atez/Bev groups (8.5 [95% confidence interval (CI): 6.1–10.7] months vs. 8.6 (95% CI: 5.3–12.1) months, respectively; p = 0.973). Regarding median overall survival (OS), no significant differences were noted between the LEN‐TACE and Atez/Bev groups (37.3 [95% CI: 31.2–60.2] months vs. 32.4 (95% CI: 19.5–NE) months, respectively; p = 0.183). Regarding adverse events (AEs) of grade ≥ 3, no significant difference was observed between the two groups. Multivariate analysis revealed that the ALBI grade 1 and low AFP levels were independent factors for OS.Conclusion: LEN‐TACE therapy may be one of the effective treatment strategies in intermediate‐stage HCC patients beyond the up‐to‐seven criteria.
- 31 May 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria
Background and Aim: This study aimed to compare the therapeutic effects and safety of lenvatinib (LEN) plus transcatheter arterial chemoembolization (LEN‐TACE) and atezolizumab plus bevacizumab (Atez/Bev) as the first‐line therapies in patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond the up‐to‐seven criteria.Methods: We enrolled 768 patients with HCC treated with first‐line systemic therapy, and 154 patients were enrolled and categorized into either the LEN‐TACE therapy (n = 42) or Atez/Bev (n = 112) groups. After propensity score matching (PSM), 72 patients (LEN‐TACE group, n = 36; Atez/Bev group, n = 36) were analyzed.Results: After PSM, the median progression‐free survival showed no significant differences between the LEN‐TACE and Atez/Bev groups (8.5 [95% confidence interval (CI): 6.1–10.7] months vs. 8.6 (95% CI: 5.3–12.1) months, respectively; p = 0.973). Regarding median overall survival (OS), no significant differences were noted between the LEN‐TACE and Atez/Bev groups (37.3 [95% CI: 31.2–60.2] months vs. 32.4 (95% CI: 19.5–NE) months, respectively; p = 0.183). Regarding adverse events (AEs) of grade ≥ 3, no significant difference was observed between the two groups. Multivariate analysis revealed that the ALBI grade 1 and low AFP levels were independent factors for OS.Conclusion: LEN‐TACE therapy may be one of the effective treatment strategies in intermediate‐stage HCC patients beyond the up‐to‐seven criteria.
- 2 February 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (4) , 971-978
Long‐Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct‐Acting Antivirals
Background and Aim: More accurate stratification of patients with chronic hepatitis C after permanent hepatitis C virus (HCV) clearance by direct‐acting antivirals (DAAs) is important for improving long‐term surveillance and treatment. The aim of this study was to stratify patients with chronic hepatitis C who are at risk of developing hepatocellular carcinoma (HCC) after HCV cure.Methods: This multicenter, retrospective cohort study included 3177 consecutive adult chronic hepatitis C patients without decompensated cirrhosis who were treated with all‐oral DAAs. The primary study endpoints were long‐term cumulative de novo HCC incidence, HCC recurrence rates, and survival. Additionally, we analyzed the development of HCC by patients without cirrhosis, stratified by age and fibrosis status according to the FIB‐4 index.Results: After exclusions, data from 3024 patients were available for analysis. The overall median follow‐up period was 6.5 years. None of the patients with non‐cirrhosis/FIB‐4 < 1.45 (n = 475) developed HCC regardless of background factors. For patients with non‐cirrhosis/FIB‐4 ≥ 3.25, older age had a greater impact on HCC incidence (log‐rank test: p = 0.038). In addition, metabolic factors, including body mass index and diabetes mellitus, were not related to HCC incidence. HCC recurrence commonly occurred within 5 years after HCV cure; nevertheless, HCV cure contributed to an improvement of survival rates.Conclusions: Age is a pivotal factor in predicting de novo HCC development following HCV cure in patients with moderate to advanced fibrosis. Conversely, patients with mild fibrosis (FIB‐4 < 1.45) may be eligible for discharge from specialized care after achieving HCV elimination.
- 2 February 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (4) , 971-978
Long‐Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct‐Acting Antivirals
Background and Aim: More accurate stratification of patients with chronic hepatitis C after permanent hepatitis C virus (HCV) clearance by direct‐acting antivirals (DAAs) is important for improving long‐term surveillance and treatment. The aim of this study was to stratify patients with chronic hepatitis C who are at risk of developing hepatocellular carcinoma (HCC) after HCV cure.Methods: This multicenter, retrospective cohort study included 3177 consecutive adult chronic hepatitis C patients without decompensated cirrhosis who were treated with all‐oral DAAs. The primary study endpoints were long‐term cumulative de novo HCC incidence, HCC recurrence rates, and survival. Additionally, we analyzed the development of HCC by patients without cirrhosis, stratified by age and fibrosis status according to the FIB‐4 index.Results: After exclusions, data from 3024 patients were available for analysis. The overall median follow‐up period was 6.5 years. None of the patients with non‐cirrhosis/FIB‐4 < 1.45 (n = 475) developed HCC regardless of background factors. For patients with non‐cirrhosis/FIB‐4 ≥ 3.25, older age had a greater impact on HCC incidence (log‐rank test: p = 0.038). In addition, metabolic factors, including body mass index and diabetes mellitus, were not related to HCC incidence. HCC recurrence commonly occurred within 5 years after HCV cure; nevertheless, HCV cure contributed to an improvement of survival rates.Conclusions: Age is a pivotal factor in predicting de novo HCC development following HCV cure in patients with moderate to advanced fibrosis. Conversely, patients with mild fibrosis (FIB‐4 < 1.45) may be eligible for discharge from specialized care after achieving HCV elimination.
- Open Access
- 8 January 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 55 (4) , 355-361
Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113
Background: JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity in chemotherapy contributes to confirm generalizability and reliability of the study itself. However, there have been no studies conducted to assess the heterogeneity among participating centers in randomized phase III trials for biliary tract cancer. Methods: The objective of this post-hoc analysis was to assess the inter-institutional heterogeneity in the overall survival and progression-free survival of patients with advanced biliary tract cancer treated with first-line chemotherapy in the JCOG1113 trial. The heterogeneity in the overall survival and progression-free survival was assessed according to three factors: hospital volume, experience in medical oncology and experience in biliary intervention. A total of 300 advanced biliary tract cancer patients were analyzed. There were no statistically significant trends observed between hospital volume, experience in medical oncology, or experience in biliary intervention and overall survival (hospital volume: adjusted trend P value = 0.6796; experience in medical oncology: adjusted trend P value = 0.4092; experience in biliary intervention: adjusted trend P value = 0.6112). Similarly, no statistically significant trends were observed between these factors and progression-free survival (hospital volume: adjusted trend P value = 0.3000; experience in medical oncology: adjusted trend P value = 0.1108; experience in biliary intervention: adjusted trend P value = 0.2898). Conclusions: This study revealed no inter-institutional heterogeneity in the overall survival and progression-free survival in the JCOG1113 study population of advanced biliary tract cancer patients.
- 8 January 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 55 (4) , 355-361
Open AccessAssessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113
Background: JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity in chemotherapy contributes to confirm generalizability and reliability of the study itself. However, there have been no studies conducted to assess the heterogeneity among participating centers in randomized phase III trials for biliary tract cancer. Methods: The objective of this post-hoc analysis was to assess the inter-institutional heterogeneity in the overall survival and progression-free survival of patients with advanced biliary tract cancer treated with first-line chemotherapy in the JCOG1113 trial. The heterogeneity in the overall survival and progression-free survival was assessed according to three factors: hospital volume, experience in medical oncology and experience in biliary intervention. A total of 300 advanced biliary tract cancer patients were analyzed. There were no statistically significant trends observed between hospital volume, experience in medical oncology, or experience in biliary intervention and overall survival (hospital volume: adjusted trend P value = 0.6796; experience in medical oncology: adjusted trend P value = 0.4092; experience in biliary intervention: adjusted trend P value = 0.6112). Similarly, no statistically significant trends were observed between these factors and progression-free survival (hospital volume: adjusted trend P value = 0.3000; experience in medical oncology: adjusted trend P value = 0.1108; experience in biliary intervention: adjusted trend P value = 0.2898). Conclusions: This study revealed no inter-institutional heterogeneity in the overall survival and progression-free survival in the JCOG1113 study population of advanced biliary tract cancer patients.